Trial Profile

A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erenumab (Primary) ; Amitriptyline; Atenolol; Bisoprolol; Cinnarizine; Flunarizine; Metoprolol succinate; Propranolol; Sodium valproate; Topiramate; Venlafaxine
Indications Migraine
Focus Therapeutic Use
Acronyms APPRAISE
Sponsors Amgen; Novartis

30 Nov 2022 This trial has been completed in Poland (End date: 30-Sep-2022), according to European Clinical Trials Database record
24 Oct 2022 Status changed from active, no longer recruiting to completed.
20 Oct 2022 This trial has been completed in Greece (Date of the global end of the trial : 30-Sep-2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com